Abstract:The aim of interventions over the respiratory microbiome in COPD is to preserve the original microbial flora, focusing in taxa with a demonstrated impact on the prognosis of the disease. Inhaled therapy is the main treatment for COPD, and chronic corticosteroid use is recommended for patients with frequent exacerbations. This therapy, however, increases both the bronchial microbial load and the abundance of potentially pathogenic bacteria in patients with low peripheral eosinophil counts, and to minimize its use in patients without peripheral eosinophilia, when possible, may avoid increases in bacterial loads of microorganisms as Haemophilus influenzae and Streptococcus pneumoniae. In exacerbations antibiotics determine a decrease in the microbial diversity, a change that persists during stability periods in frequent exacerbators. High-diversity bronchial microbiomes are enriched in non-dominant genera and determine low exacerbation frequencies and survival improvement. Limiting the antibiotic use to the treatment of exacerbations which would clearly benefit would favor the diversity of the respiratory microbiome and may have a positive impact on quality of life and survival. Oral antiseptics have shown and effect on the bronchial microbiome that was associated with improvements in quality of life, and the gut microbiome may be also modified through the oral administration of probiotics or prebiotics, that potentially may determine decreases in lung inflammation and bronchial hyperreactivity. High fiber diets also favor the production of anti-inflammatory molecules by the digestive flora, which would reach the respiratory system through the bloodstream. Interventional approaches favoring the preservation of the respiratory microbiome in COPD need first to select accurately the patients who would benefit from long-term inhaled corticosteroids and antibiotic treatments during exacerbations, under the hypothesis that keeping a respiratory microbiome close to the healthy subject would favor the respiratory health. Additionally, high fiber diets may be able to modify the gut microbiome and influence the respiratory system through the gut-lung axis. Therapeutic approaches targeting the microbiome to improve COPD, however, still require clinical validation and the identification of patient subtypes who would benefit the most with their use.

[Chronic Bronchial Infection in Stable COPD]

The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

Time to re-set our thinking about airways disease: lessons from history, the resurgence of chronic bronchitis / PBB and modern concepts in microbiology

Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease

Rethinking bronchiectasis as an inflammatory disease

The microbiome in bronchiectasis

Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects

[Chronic bronchitis, COPD]

The roles of bacteria and viruses in COPD-Bronchiectasis association: A prospective cohort study

Role Of Subacute Bronchial Infection In Patients With Severe Asthma Candidates For Biologic Therapy

Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes Before and after Treatment of AECOPD, a Longitudinal and Cross-Sectional Study.

Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Chronic obstructive pulmonary disease and the airway microbiome: A review for clinicians

Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Respiratory Pathogens at Exacerbation in Chronic Bronchitis With Airway Bacterial Colonisation: A Cohort Study

Current management of bronchiectasis: review and 3 case studies

Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies

What is the future of inhaled antibiotics for bronchiectasis?

Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention